Supriya Lifescience Ltd SUPRIYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₹873.25
- Day Range
- ₹835.95–874.85
- 52-Week Range
- ₹545.50–1,085.00
- Bid/Ask
- ₹838.10 / ₹838.60
- Shares Outstanding
- 80.48M
- Market Cap
- ₹67.53B
- Volume/Avg
- 138,400 / 300,540
Key Statistics
- Price/Earnings (Normalized)
- 35.43
- Price/Sales
- 8.05
- Dividend Yield (Trailing)
- 0.11%
- Dividend Yield (Forward)
- 0.11%
- Dividend Payment Schedule
- —
- Total Yield
- 0.11%
Company Profile
Supriya Lifescience Ltd is a life sciences company that develops and manufactures niche Active Pharmaceutical Ingredients (APIs), formulations, and CMO/CDMO solutions. It has a diversified portfolio across various therapeutic segments, including anaesthetic, analgesic, antihistamine, vitamins, anti-asthmatic, anti-allergic, antihypertensive, and others. Additionally, the company provides CDMO services, offers finished dosage formulations such as Sevoflurane USP liquid for inhalation, Semaglutide injection, Iohexol injection, Tramadol tablet IR, etc., and has various products in its research and development pipeline. Geographically, the company derives the majority of its revenue from Europe, and the rest comes from its business in Asia, North America, Latin America, and other markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,310
Valuation
|
Metric
|
SUPRIYA
|
|---|---|
Price/Earnings (Normalized) | 35.43 |
Price/Book Value | 5.87 |
Price/Sales | 8.05 |
Price/Cash Flow | 30.38 |
Price/Earnings
SUPRIYA
Financial Strength
|
Metric
|
SUPRIYA
|
|---|---|
Quick Ratio | 2.56 |
Current Ratio | 4.40 |
Interest Coverage | 154.15 |
Quick Ratio
SUPRIYA
Profitability
|
Metric
|
SUPRIYA
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SUPRIYA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&<?CX% | LOCK|!dnr | $130B | |||
| Moderna Inc
MRNA
| LOCK|Rc<#Kl^ | LOCK|bC | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>BmypzS | LOCK|>Rqr! | $83B | |||
| argenx SE ADR
ARGX
| LOCK|J$w%$@y | LOCK|?l | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$Mfp<& | LOCK|Cw | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#gG^t$ | LOCK|M%F$$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|sZ%^Rmf^ | LOCK|#mfL | $28B | |||
| Incyte Corp
INCY
| LOCK|Kk<>WdW | LOCK|&Q@ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|<#bWjG | LOCK|n% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|NDGSWK> | LOCK|gN | $14B |
United States